BeiGene nets $875.5mm via Hong Kong IPO

BeiGene Ltd. (immuno-oncology) netted $875.5mm through its initial public offering on the Main Board of the Stock Exchange of Hong Kong Ltd. (SEHK). The company sold 65.6mm ordinary shares at $13.76 (the mid-point of its $12.03-14.22 range). Of the total, 5.9mm shares were offered to the public in Hong Kong and 59.7mm shares were offered globally. BeiGene completed its US initial public offering on the Nasdaq Global Select Market in February 2016, through which it netted $170mm with the sale of 7.6mm American Depositary Shares (representing 98.7mm ordinary). Current proceeds will go towards development, regulatory activities, and future commercialization of zanubrutinib (mantle cell lymphoma), tislelizumab (classical Hodgkin's lymphoma), and pamiparib (solid tumors including ovarian, gastric, and brain tumors), and will also support pipeline expansion in cancer and possibly other indications.